Literature DB >> 23381371

Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?

Peter Rossing1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23381371     DOI： 10.1038/nrneph.2013.13

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

Authors:  Gearoid M McMahon; John P Forman
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

2.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

3.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

4.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

5.  Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.

Authors:  Pablo E Pergola; Melissa Krauth; J Warren Huff; Deborah A Ferguson; Stacey Ruiz; Colin J Meyer; David G Warnock
Journal:  Am J Nephrol       Date:  2011-04-21       Impact factor: 3.754

6.  Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

Authors:  Lauren M Aleksunes; Michael J Goedken; Cheryl E Rockwell; Juergen Thomale; Jose E Manautou; Curtis D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

7.  Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.

Authors:  P Rossing; E Hommel; U M Smidt; H H Parving
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

Review 8.  Albuminuria: a target for treatment of type 2 diabetic nephropathy.

Authors:  Dick de Zeeuw
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

9.  Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.

Authors:  Carla Zoja; Daniela Corna; Valeria Nava; Monica Locatelli; Mauro Abbate; Flavio Gaspari; Fabiola Carrara; Fabio Sangalli; Giuseppe Remuzzi; Ariela Benigni
Journal:  Am J Physiol Renal Physiol       Date:  2012-11-07
  9 in total
  14 in total

1.  Antifibrotic therapy: is an antioxidative regimen the answer?

Authors:  Frank Strutz
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

2.  Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease.

Authors:  Madhav C Menon; Peter Y Chuang; John C He
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-18

Review 3.  Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment.

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

Review 4.  Oxidative Stress in Chronic Obstructive Pulmonary Disease.

Authors:  Peter J Barnes
Journal:  Antioxidants (Basel)       Date:  2022-05-13

Review 5.  Drug discovery in renal disease--towards a more efficient framework.

Authors:  Toshio Miyata; Tsuyoshi Ando; Hisami Hiragi; Kanako Watanabe; Fumi Yamamoto; Douglas E Vaughan; Tatsuo Kurokawa; Yoshiteru Oshima; Charles van Ypersele de Strihou; Masahiro Takeuchi
Journal:  Nat Rev Nephrol       Date:  2014-03-18       Impact factor: 28.314

Review 6.  New anti-inflammatory targets for chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

7.  Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats.

Authors:  Yifei Zhong; Xianwen Zhang; Xianfan Cai; Ke Wang; Yiping Chen; Yueyi Deng
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

8.  Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects.

Authors:  Keisuke Ishizawa; Yuki Izawa-Ishizawa; Noriko Yamano; Maki Urushihara; Takumi Sakurada; Masaki Imanishi; Shoko Fujii; Asami Nuno; Licht Miyamoto; Yoshitaka Kihira; Yasumasa Ikeda; Shoji Kagami; Hiroyuki Kobori; Koichiro Tsuchiya; Toshiaki Tamaki
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

9.  Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids.

Authors:  Ian M Copple; Luke M Shelton; Joanne Walsh; Denise V Kratschmar; Adam Lister; Alex Odermatt; Christopher E Goldring; Albena T Dinkova-Kostova; Tadashi Honda; B Kevin Park
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

10.  Prostaglandin I2 Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?

Authors:  Madhav C Menon; John C He
Journal:  Diabetes       Date:  2016-05       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.